AstraZeneca - Public Comps and Valuation Multiples

AstraZeneca Overview

About AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

Founded

1992

HQ

Employees

94.3K+

Website

astrazeneca.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $43.8B

LTM EBITDA $14.7B

EV

$251B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

AstraZeneca Financials

AstraZeneca has a last 12-month revenue of $43.8B and a last 12-month EBITDA of $14.7B.

In the most recent fiscal year, AstraZeneca achieved revenue of $68.0B and an EBITDA of $19.4B.

AstraZeneca expects next 12-month revenue of XXX and NTM EBITDA of XXX

See AstraZeneca valuation multiples based on analyst estimates

AstraZeneca P&L

	FY 2022	FY 2023	FY 2024	LTM	NTM
Revenue	$55.8B	$57.6B	$68.0B	$43.8B	XXX
Gross Profit	$40.2B	$47.2B	$55.2B	XXX	XXX
Gross Margin	72%	82%	81%	XXX	XXX
EBITDA	$11.4B	$16.9B	$19.4B	$14.7B	XXX
EBITDA Margin	20%	29%	29%	34%	XXX
Net Profit	$4.1B	$7.5B	$8.9B	XXX	XXX
Net Margin	7%	13%	13%	XXX	XXX
Net Debt	$27.8B	$27.2B	$29.2B	XXX	XXX

Financial data powered by Morningstar, Inc.

AstraZeneca Stock Performance

As of February 21, 2025, AstraZeneca's stock price is GBP 116 (or $146).

AstraZeneca has current market cap of GBP 180B (or $226B), and EV of GBP 199B (or $251B).

See AstraZeneca trading valuation data

AstraZeneca Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$251B	$226B	XXX	XXX	XXX	XXX	$8.42

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

AstraZeneca Valuation Multiples

As of February 21, 2025, AstraZeneca has market cap of $226B and EV of $251B.

AstraZeneca's trades at 4.5x LTM EV/Revenue multiple, and 13.5x LTM EBITDA.

Analysts estimate AstraZeneca's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for AstraZeneca and 10K+ public comps

AstraZeneca Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$251B	XXX	XXX	XXX
EV/Revenue	3.7x	XXX	XXX	XXX
EV/EBITDA	12.9x	XXX	XXX	XXX
P/E	25.5x	XXX	XXX	XXX
P/E/Growth	0.8x	XXX	XXX	XXX
EV/FCF	27.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get AstraZeneca Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

AstraZeneca Valuation Multiples

AstraZeneca's NTM/LTM revenue growth is 4%

AstraZeneca's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.4M for the same period.

Over next 12 months, AstraZeneca's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate AstraZeneca's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for AstraZeneca and other 10K+ public comps

AstraZeneca Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	18%	XXX	XXX	XXX	XXX
EBITDA Margin	29%	XXX	XXX	XXX	XXX
EBITDA Growth	15%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	33%	XXX	XXX	XXX	XXX
Revenue per Employee	$0.7M	XXX	XXX	XXX	XXX
Opex per Employee	$0.4M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	1%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	36%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	25%	XXX	XXX	XXX	XXX
Opex to Revenue	62%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Medical Devices

Consumer SaaS

Streaming Platforms

AdTech Software

Climate Tech

GRC Software

Developer Tools

Explore Valuation Multiples by Industry